Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the pric

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached

GRMN, LTH and DXCM tap the health and fitness boom through premium clubs, connected wearables and gl

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a l

Dexcom (DXCM) delivered strong Q2/26 results with 13.1% revenue growth, 49.7% operating income growt

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cy

JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the pric

Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and rais

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and raises t

U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other g

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

Benchmark analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

BTIG analyst Marie Thibault maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target

Revenue: Worldwide revenue of $1.31 billion, up 13% reported and 12% organic year-over-year.US Reven

DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript

DexCom NASDAQ: DXCM reported second-quarter 2026 revenue growth of 13% from a year earlier, supporte

DexCom (DXCM) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estima

Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates ​on T

DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billio

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.

They may profit from the rapidly growing GLP-1 market in very different ways.

Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays stron

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

Dimensional Fund Advisors LP boosted its stake in DexCom, Inc. (NASDAQ: DXCM) by 1.3% in the first q

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM de

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings

Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating DexCom, Inc. (N

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigati

The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health te

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada,

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating an

FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time G

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raise

https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients n

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care